Seres Therapeutics, Inc. (MCRB)

Seres Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	126.33	7.13	144.93	33.22	34.51
Revenue Growth (YoY)	1672.24%	-95.08%	336.33%	-3.74%	22.07%
Gross Profit	126.33	7.13	144.93	33.22	34.51
Selling, General & Admin	87.74	79.69	69.26	30.78	24.75
Research & Development	145.86	172.92	141.89	90.57	80.14
Other Operating Expenses	0.7	1	-1.73	0	1.49
Operating Expenses	234.31	253.62	209.42	121.35	106.38
Operating Income	-107.98	-246.49	-64.49	-88.13	-71.88
Interest Expense / Income	13.18	6.02	2.91	2.92	0.5
Other Expense / Income	-7.44	-2.35	-1.83	-1.93	-2.1
Pretax Income	-113.72	-250.16	-65.58	-89.13	-70.28
Net Income	-113.72	-250.16	-65.58	-89.13	-70.28
Shares Outstanding (Basic)	128	108	92	80	57
Shares Outstanding (Diluted)	128	108	92	80	57
Shares Change	18.44%	17.86%	14.93%	40.85%	39.04%
EPS (Basic)	-0.89	-2.31	-0.72	-1.12	-1.24
EPS (Diluted)	-0.89	-2.31	-0.72	-1.12	-1.24
Free Cash Flow	-125.33	-238.64	-2.88	-94.2	-77.52
Free Cash Flow Per Share	-0.98	-2.21	-0.03	-1.18	-1.37
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-85.48%	-3458.05%	-44.50%	-265.33%	-208.31%
Profit Margin	-90.02%	-3509.50%	-45.25%	-268.33%	-203.68%
Free Cash Flow Margin	-99.21%	-3347.88%	-1.99%	-283.61%	-224.67%
EBITDA	-85.43	-232.28	-53.45	-77.31	-59.95
EBITDA Margin	-67.63%	-3258.75%	-36.88%	-232.76%	-173.73%
Depreciation & Amortization	15.11	11.85	9.22	8.89	9.83
EBIT	-100.55	-244.14	-62.67	-86.2	-69.78
EBIT Margin	-79.59%	-3425.04%	-43.24%	-259.53%	-202.22%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).